SUPPLEMENTARY FIGURES

A Expression of UBE2C in KIRC based on Sample types

B Expression of UBE2C in KIRC based on nodal metastasis status

C Expression of UBE2C in KIRC based on individual cancer stages

D Expression of UBE2C in KIRC based on tumor grade

Supplementary Figure 1. Association of UBE2C mRNA expression with clinicopathologic characteristics. (**A**) sample types. (**B**) nodal metastasis status. (**C**) individual cancer stages. (**D**) tumor grade.

Supplementary Figure 2. The prognostic value of mRNA levels of UBE2C factor and subclinical factors in ccRCC patients. (**A**) The overall survival of UBE2C in PRCC for all cases (*P* < 0.0001). (**B**) The overall survival of UBE2C and gender in PRCC (*P* < 0.0001). (**C**) The overall survival of UBE2C and tumor grade in PRCC (*P* < 0.0001). (**D**) The overall survival of UBE2C and race in PRCC (*P* < 0.0001).

Supplementary Figure 3. The relationship of UBE2C with checkpoint inhibitors in PRCC. (**A**) The Pearson correlation of UBE2C with 47 different checkpoint inhibitors and 15 of them was displayed. (**B** and **C**) The coefficient and *p*-value of UBE2C and CDC20 were shown on the graph.